Abstract:Introduction & Objective: Investigate the feasibility and efficacy of a telemedicine program in institutionalized elderly people with insulin-treated diabetes. Methods: This multicenter, prospective study comprised of three two-week phases: Phase 1 (baseline): blind CGM (Freestyle Libre Pro®); Phase 2a: CGM (Freestyle Libre2®) without alarms; Phase 2b: CGM with alarms for hypo and hyperglycemia. Two telemedicine visits from the reference diabetes units to adjust the treatment before phases 2a and 2b. The insulin treatment was tracked using the Insulclock® connected insulin pen cap. The caregivers’ opinion about the program was measured. Feasibility criteria included the number of eligible patients, recruitment, attrition and the capture of glucose readings. The insulin or antidiabetic drugs changes were recorded. Results: From 82 eligible residents (87.7 +7.1, 68-102 y, 56% women, baseline HbA1c 6.9 <u>+</u>1.6) at 7 nursing homes, 54 completed all the procedures. The caregivers expressed an overall positive view of the program (3.8 out of 4 points); greater convenience (4.5 out of 5 points) and potential to reduce hypoglycemia (3.7 out of 5 points) by using Freestyle Libre2® over glucometer. The rate of glucose events <70 mg/dl in every phase (mean +SD) decreased: 4.9 +6.2, 3 +3.8, and 2.1 +3.1 (p 0.036). GMI and TIR 70-180 increased: 7.1 +1.2, 7.2 +1.4, 7.5 +1.7 (p 0.01); 65.6 +24.8, 65.1 +25.2, 60.4 +26.4 (p 0.02), respectively. The number of insulin injections (mean +SD): (1.2 +0.9 to 0.9 +0.8; p 0.02), and basal insulin dose (median) (16 to 14 IU; p 0.0003) decreased. The number of rapid insulin doses increased: 1.6 +3.8 to 2.9 +4.3 (p 0.02). Conclusion: A telemedicine program using CGM is well-perceived by caregivers and achieves a safer and more adequate glycemic profile in the challenging population of institutionalized older people with diabetes treated with insulin. Disclosure F. Gomez-Peralta: Advisory Panel; Abbott. Speaker's Bureau; Abbott. Advisory Panel; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Insulcloud S.L. Speaker's Bureau; Medtronic. Advisory Panel; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Advisory Panel; Sanofi. C. Abreu: None. E.S. Mazo: None. Funding Abbott Diabetes Care Investigator Initiated Study (ADC-OUS-IIS-20-55)

Continuous glucose monitoring in older people with diabetes receiving home care-a feasibility study

Continuous glucose monitoring in older people with diabetes and memory problems: a mixed-methods feasibility study in the UK

1986 Hypoglycaemia in older people with diabetes and symptoms suggestive of hypoglycaemia - continuous glucose monitoring (CGM) study

Real-time Continuous Glucose Monitoring Versus Conventional Glucose Monitoring in Critically Ill Patients: a Systematic Review Study Protocol.

Continuous Glucose Monitoring With Geriatric Principles in Older Adults With Type 1 Diabetes and Hypoglycemia: A Randomized Controlled Trial

Mixed methods study on the feasibility of implementing periodic continuous glucose monitoring among individuals with type 2 diabetes mellitus in a primary care setting

Continuous Glucose Monitoring in Older Adults: What We Know and What We Have Yet to Learn

947-P: Glycemic Control Utilizing Continuous Glucose Monitoring vs. Point-of-Care Testing in Older Adults with Type 2 Diabetes in Long-Term Care Facilities

Health literacy of patients using continuous glucose monitoring

Use of Continuous Glucose Monitoring in Older Adults: A Review of Benefits, Challenges and Future Directions

Clinical features of type 1 diabetes in older adults and the impact of intermittently scanned continuous glucose monitoring: An Association of British Clinical Diabetologists (ABCD) study

Continuous Glucose Monitoring Workflows for Elderly, Cognitively Impaired Adults with Type 2 Diabetes

Nocturnal hypoglycemia is underdiagnosed in older people with insulin-treated type 2 diabetes: The HYPOAGE observational study

195-OR: Efficacy and Feasibility of a Telemedicine Program for Institutionalized Elderly People with Insulin-Treated Diabetes Using Continuous Glucose Monitoring and a Connected Insulin Pen Cap—The Trescasas Study

Glycaemic outcomes in people living with diabetes under 65 and over 65 years old using an intermittently scanned continuous glucose monitoring system

Relationship Between Sensor-Detected Hypoglycemia and Patient-Reported Hypoglycemia in People With Type 1 and Insulin-Treated Type 2 Diabetes: The Hypo-METRICS Study

Trends in Intermittent Scanning Continuous Glucose Monitoring Usage in The Netherlands—An Opportunity for Elderly Individuals with Diabetes

Performance of a Novel Continuous Glucose Monitoring Device in People With Diabetes

[Continuous glucose monitoring devices in people over 65 years: literature review]

Digital algorithm-guided insulin therapy in home healthcare for elderly persons with type 2 diabetes: A proof-of-concept study

Feasibility of continuous glucose monitoring in patients with type 1 diabetes at two district hospitals in Neno, Malawi: a randomised controlled trial